## Table of Content

<table>
<thead>
<tr>
<th></th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Presidential report</td>
</tr>
<tr>
<td>2</td>
<td>Secretary-General’s report</td>
</tr>
<tr>
<td>3</td>
<td>Vice-presidents’ reports</td>
</tr>
<tr>
<td>4</td>
<td>Treasurer’s report</td>
</tr>
<tr>
<td>5</td>
<td>Presentation and approval of EAACI Executive Committee 2019-2021</td>
</tr>
<tr>
<td>6</td>
<td>Presidential Programme 2019-2021</td>
</tr>
<tr>
<td>7</td>
<td>Any other business</td>
</tr>
</tbody>
</table>
Presidential report
Strategic plan 2017 – 2019: Key deliverables

- **EAACI White Paper on Research, Innovation and Quality Care**
- **EAACI Scientific Output Roadmap: VP Science, Science Committee, 3 new Guidelines**
- **Innovative educational portfolio**
- **Marketing and operational plan to promote Allergy Speciality**
- **“My membership. My EAACI” and “My Annual Meeting” programmes**
- **EAACI –NAS dual membership**
- **Optimised financing system and organisational effectiveness**
Congress, Focused Meetings; highest attendance and best quality worldwide
Master Classes and Allergy Schools
fully booked, – growing interest

EAACI Scientific Output
• Top journals (projected IF increase for all 3 EAACI journals)
• Guidelines, PP, consensus documents, Atlases
• NEW: Methodology Committee
• NEW: EAACI Fellows
• NEW: Revised nomenclature for allergic diseases
• NEW: PhARF award

NEW: Allergy College
Development of e-learning resources
EAACI Media Library

From Munich to Lisbon (1)
11 379 members;
34 societies signed the dual
EAACI-NAS agreement;
434 new members

4

5

Strategic Forum for high-level dialogue
Partnerships

NEW:

Robust finances
- ≈ 12 milion € turnover/year
- own capital increase ≈ 2.5 million €
(total ≈ 5.5 million €)
Revised by-laws for:
1. Sections/IGs/WGs
2. Use of EAACI budgets
3. NAS Committee and International Societies Council

NEW: Criteria for evaluation of the activity of Sections/IGs/WGs

New EAACI Section: Allied Health/Primary Care
Elections

1. Sections/IGs/WGs boards
2. EAACI President (resignation of President Elect on 28th February 2019)
3. 2019 – 2021 Executive Committee
4. 2019 – 2021 EAACI Committees Chairs:
   - Science Committee – Joaquin Sastre
   - Scientific Communication – Stephanie Dramburg
   - NAS Committee – Cevdet Ozdemir
   - Exam Committee – Knut Brochow
   - CME Committee – Jean Luc Fauquert
   - Patient Organisations Committee – Mary Jane Marchisotto and Carla Jones
   - Methodology Committee – Walter Canonica
   - Guidelines Committee – Antonella Muraro
   - Nomenclature Committee – Maria Beatrice Bilo
EAACI 2019 Congress

i. > 8500 Participants
ii. 2026 abstracts
iii. 41 Symposia, 14 Sister Society Symposia, 6 Thematic Symposia, 1 JMA Sci Symposium
iv. 35 European CME credits

EAACI Focused Meetings

- FAAM 2018: > 1000 participants
- ISAF 2018: twin track; > 300 participants
- RHINA 2019: “sold-out”
- SAM 2019: > 200 participants
EAACI VP Science/ Science Committee

i. Guidelines
ii. Task Forces/Position Papers/Consensus Documents
iii. Scientific Communication
iv. Scientific Programme Committee
v. Nomenclature Committee
vi. Methodology Committee
vii. m-Health/e-Health
viii. EAACI Fellowships and Mentorship Programmes/Allergy College

EAACI Guidelines

i. HDM AIT for allergic asthma
ii. Atopic dermatitis
iii. Biologics in allergic diseases and asthma
iv. Revision of the Food allergy and anaphylaxis guidelines

EAACI Scientific Output
• Basic course in “omic” techniques in allergy
The EAACI Community is growing fast: We are more than 11,000 members!

NAS platform: 56 societies

International Societies Council: 23 societies
Collaboration with European and International Organisations

PRACTALL: The role of exposome in allergy and asthma; Immune modulation for food allergy

ICON: Ocular allergy; The importance of allergic disease in public health: an iCAALL statement

MoU, joint TF and meetings with APAACI, ERS, EFA, ERhS, ESCD, IPCRG, JSA
European Strategic Forum on Allergic Diseases and Asthma – 17 November 2018

**Prioritising research challenges and funding for allergy, asthma and the need for translational research**

1. World Health Organisation
2. Paul Erlich Institute
3. UEMS
4. The European Federation of Allergy and Airways Diseases Patients' Associations (EFA)
5. The French National Institute of Health and Medical Research (INSERM)

2. European Respiratory Society
2. European Society for Immunodeficiencies
3. European Pediatric Association
4. The Global Alliance against Chronic Respiratory Diseases (GARD)

3. Key opinion leaders
2. Industry representatives
European Strategic Forum on Allergic Diseases and Asthma

• Prioritising research challenges and funding for allergy, asthma and the need for translational research
Thank you for supporting EAACI!

EAACI is leading the way towards a sustainable management programme for allergy and asthma ensuring better health and outcomes at a lower cost
Approval of the Presidential Report
Secretary General’s report
ExCom Proposal

IG Allied Health & Primary Care to be an EAACI Section
Vice-President’s reports
Vice-President Congresses
## EAACI 2019

<table>
<thead>
<tr>
<th></th>
<th>EAACI Annual Congress -1 weeks out</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2019 (status on 02 June)</td>
</tr>
<tr>
<td>Paying participants</td>
<td>5389</td>
</tr>
<tr>
<td>All participants</td>
<td>8614</td>
</tr>
<tr>
<td>Abstracts</td>
<td>1737</td>
</tr>
<tr>
<td>Late breaking abstracts</td>
<td>289</td>
</tr>
<tr>
<td>Patent abstracts</td>
<td>8</td>
</tr>
</tbody>
</table>
EAACI 2020 – London
06 – 11 June 2019
ExCeL London
Innovations in the last term

- Contract flexibility
- EAACI TV
- Full coverage Media Library
- New sponsor items
- RHINA meeting
- Discontinuation of print items
- New operating procedures at Headquarters
- New headquarter staff
- Greenbox
- E-posters
Vice-President Education & Specialty
UEMS/EAACI contract

• Contract finalized and ready for signing during Annual Congress
• Main improvements:
  ➢ Contract duration limited to 1 year (will renew automatically if not terminated)
  ➢ Partial replacement of reviewers and extension of EBAACI group (10 instead of 6 reviewers)
    → increase review quality and reviewer response time
    → earlier accreditation of our events
    → earlier promotion through Marketing team possible
  ➢ Allocation process of reviewer fee to different parties streamlined
**Winter School 2019, 24-27 January 2019 in Trysil, Norway**

<table>
<thead>
<tr>
<th>Topics</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EAACI Contribution</td>
<td>70K</td>
</tr>
<tr>
<td>Registration</td>
<td>65 paying participants; 17 non-paying participants (faculty and staff)</td>
</tr>
<tr>
<td>Abstracts</td>
<td>106 submitted; 70 accepted</td>
</tr>
<tr>
<td>Scientific Programme</td>
<td>6 lectures, 19 oral abstracts and 46 posters</td>
</tr>
<tr>
<td>Projected financial outcome with EAACI contribution</td>
<td>- 1,000 EUR</td>
</tr>
<tr>
<td>Projected financial outcome without EAACI contribution</td>
<td>- 71,000 EUR</td>
</tr>
</tbody>
</table>
### Topics

<table>
<thead>
<tr>
<th>Registration</th>
<th>Description</th>
</tr>
</thead>
</table>
| Registrations | - 107 total delegates  
|              | - 82 paid delegates  
|              | - 16 faculty members  |

<table>
<thead>
<tr>
<th>Scientific Programme</th>
<th>Description</th>
</tr>
</thead>
</table>
|                      | - 20 lectures including workshops  
|                      | - 6 oral abstracts  
|                      | - 20 posters  |

### Registrations
- 107 total delegates  
- 82 paid delegates  
- 16 faculty members

### Scientific Programme
- 20 lectures including workshops  
- 6 oral abstracts  
- 20 posters

### Total Income
- 28,600 EUR

### EAACI contribution
- 33,000 EUR

### Total Expenses
- 57,000 EUR

### Projected financial outcome with EAACI contribution
- 4,600 EUR

### Projected financial outcome without EAACI contribution
- 28,400 EUR
### Topics

<table>
<thead>
<tr>
<th>Registrations</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>- 66 total delegates</td>
</tr>
<tr>
<td></td>
<td>- 48 paid delegates</td>
</tr>
<tr>
<td></td>
<td>- 14 faculty members</td>
</tr>
<tr>
<td>Scientific Programme</td>
<td>- 18 lectures including workshops</td>
</tr>
<tr>
<td></td>
<td>- 7 case reports presentation</td>
</tr>
</tbody>
</table>

| Total Income        | 35,050 EUR                                       |
| EAACI Contribution  | 25,000 EUR                                       |
| Total Expenses      | 45,000 EUR                                       |

**Projected financial outcome with EAACI contribution** 15,050 EUR

**Projected financial outcome without EAACI contribution** - 9,950 EUR
### Clinical Fellowship 2019 (approved 2019 budget EUR 30’000)

<table>
<thead>
<tr>
<th>Length of Fellowship</th>
<th>Award (EUR)</th>
<th>Applications received</th>
<th>Proposal for ExCom approval</th>
<th>Proposed 2019 budget spend</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 months</td>
<td>EUR 3’000</td>
<td>14</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Research Fellowship 2019 (approved 2019 budget EUR 165’000)

<table>
<thead>
<tr>
<th>Length of Fellowship</th>
<th>Award (EUR)</th>
<th>Applications received</th>
<th>Proposal for ExCom approval</th>
<th>Proposed 2019 budget spend</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Short-term) 3 months</td>
<td>EUR 5’000</td>
<td>4</td>
<td></td>
<td>12’000</td>
</tr>
<tr>
<td>(Medium-term) 6 months</td>
<td>EUR 10’000</td>
<td>7</td>
<td></td>
<td>50’000</td>
</tr>
<tr>
<td>(Long-term) 12 months</td>
<td>EUR 20’000</td>
<td>6</td>
<td></td>
<td>80’0000</td>
</tr>
</tbody>
</table>
Future Events Overview

<table>
<thead>
<tr>
<th>Event Name</th>
<th>Date</th>
<th>City/Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Master Class on Allergen Immunotherapy</td>
<td>1-2 November 2019</td>
<td>London, UK</td>
</tr>
<tr>
<td>AS Food Allergy</td>
<td>05-07 December 2019</td>
<td>Paris, France</td>
</tr>
<tr>
<td>18th Immunology Winter School</td>
<td>23-26 January 2020</td>
<td>Chamonix, France</td>
</tr>
<tr>
<td>AS Anaphylaxis: Causes, Prevention and Management</td>
<td>26-28 March 2020 or 9-11 April 2020</td>
<td>Izmir, Turkey</td>
</tr>
<tr>
<td>Master Class Perioperative Allergy</td>
<td>April 2020 (pre-/post-DHM)</td>
<td>Verona, Italy</td>
</tr>
</tbody>
</table>
## Speaker Support 2018 overview

<table>
<thead>
<tr>
<th>Month</th>
<th>Countries</th>
</tr>
</thead>
</table>
| Apr 2018 | • Ukraine (2)  
|          | • Spain (2)  
|          | • Turkey (2)  |
| May 2018 | • South Korea (1)  
|          | • Romania (3)  
|          | • Portugal (1)  |
| Jun 2018 | • Georgia (2)  
|          | • Mexico (1)  
|          | • Japan (2)  |
| Aug 2018 | • Argentina (2)  |
| Sep 2018 | • Netherlands (1)  
|          | • Italy (2)  
|          | • Peru (2)  
|          | • Macedonia (1)  
|          | • Hong Kong (1)  |
| Oct 2018 | • United Kingdom (1)  
|          | • Thailand (3)  
|          | • Italy (3)  
|          | • Italy (1)  
|          | • Brazil (2)  |
| Nov 2018 | • Zimbabwe (2)  
|          | • South Korea (1)  
|          | • Uruguay (1)  
|          | • Bulgaria (1)  
|          | • Turkey (2)  |
| Dec 2018 | • Italy (3)  |
EAACI Knowledge Exam 2019

• Received 74 applications (70 EAACI members and 4 non-members)
• 15 European and 16 non-European countries (including Brazil, Egypt, India, Japan, Mexico, Qatar and Sri Lanka)
• From the original 74 applicants
  ➢ 53 registered
     41 basic exam
     12 pediatric exam
• 10 applicants were granted with UEMS support
EAACI Knowledge Exam 2020 Promotion Video

Content will be captured at Annual Congress in Lisbon:

➢ Mix of short clips from EAACI Family (e.g. “why is it important to take the exam?”)
➢ Interviews with exam participants
➢ Addition of impressions from the exam (pictures)
2015-2019
4 Years VP Education and Speciality
Thank you

All my Committee Chairs

My Family

The EAACI Headquarters

Events and Education

Vivianne Knerr

Thomas Greif
Events and Education Manager

Adrienn Palme
Congress and Events Officer

Roxana Radulescu
Junior Congress and Events Officer
Vice-President
Communication & Membership
Membership

Number of active members - 2019 (May)

Active members 2019 (May)          Individual Members: 6.103          Junior Members: 5.276
Membership

Age groups

Active members 2019 (May)
Individual Members: 6.103
Junior Members: 5.276
Membership

Top 10 countries

- Italy: 1386
- Spain: 1132
- United Kingdom: 1103
- Germany: 919
- Russian Federation: 612
- The Netherlands: 561
- Turkey: 545
- Portugal: 478
- United States: 470
- Romania: 459
International Membership: Top 10 countries

- United States: 470
- India: 426
- Brazil: 323
- China: 274
- Canada: 259
- Mexico: 258
- Australia: 229
- Japan: 197
- Republic of Korea: 195
- Islamic Republic of Iran: 187
EAACI e-Strategy

Guidelines
Abstracts
Books
Posters
Papers

EAACI Newsletters

Global Atlas of Skin Allergy

Discovering EAACI

Keynote speakers in Lisbon

250 speakers
and over

EAACI TV Webcasts

We look forward to meeting you all in Lisbon in June.
Scientific Journals & Books

6.048 IF

4.137 IF

3.539 IF
Science media Team

Edward Knol
Scientific Media editor

Tomas Chivato
Science editor

Charlie Bonnet des Tuves
Marketing and Public Affairs Manager

Dario Antolin-Amérgio
Newsletter editor

Florin-Dan Popescu
Social Media editor

Sylwia Smolinska
Web editor

Ana Antunes
Scientific Content Officer

Chiara Hartmann
Public Affairs Specialist

Elodie Zufferey
Marketing & Communications Officer
Approval of the Secretary General and VP’s Report
Treasurer’s Report
## Own Capital development

<table>
<thead>
<tr>
<th>Year</th>
<th>Own Capital (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 2013</td>
<td>2'932.2</td>
</tr>
<tr>
<td>December 2014</td>
<td>4'060.6</td>
</tr>
<tr>
<td>December 2015</td>
<td>3'821.6</td>
</tr>
<tr>
<td>December 2016</td>
<td>3'874.9</td>
</tr>
<tr>
<td>December 2017</td>
<td>5'351.7</td>
</tr>
<tr>
<td>December 2018</td>
<td>5'700.4</td>
</tr>
</tbody>
</table>

accumulated profit over the years
Capital invested at ZKB
devolution of Market Value

<table>
<thead>
<tr>
<th>'000 €</th>
<th>Nominal as of 31.12.</th>
<th>Market Value as of 31.12.</th>
<th>Interest as of 31.12.</th>
<th>in %</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>3'130</td>
<td>3'311</td>
<td>62.1</td>
<td>1.98%</td>
</tr>
<tr>
<td>2017</td>
<td>3'130</td>
<td>3'379</td>
<td>95.1</td>
<td>3.04%</td>
</tr>
<tr>
<td>2016</td>
<td>3'110</td>
<td>3'314</td>
<td>111.7</td>
<td>3.59%</td>
</tr>
<tr>
<td>2015</td>
<td>3'040</td>
<td>3'193</td>
<td>106.8</td>
<td>3.51%</td>
</tr>
<tr>
<td>2014</td>
<td>2'950</td>
<td>3'325</td>
<td>115.4</td>
<td>3.91%</td>
</tr>
<tr>
<td>2013</td>
<td>2'950</td>
<td>3'251</td>
<td>116.7</td>
<td>3.96%</td>
</tr>
</tbody>
</table>

Graphs showing Nominal Value, Market Value, and Interest as of 31.12 from 2013 to 2018.
## Statement 2018 - Income as of December 31st

<table>
<thead>
<tr>
<th>2018 (YTD) in EURO</th>
<th>Statement December 31st 2018</th>
<th>Budget 2018 ExCom 02.02.2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Income</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Income</td>
<td>4'756'024</td>
<td>4'686'520</td>
</tr>
<tr>
<td>Membership Subscription</td>
<td>323'300</td>
<td>300'000</td>
</tr>
<tr>
<td>Income from Founder Sponsor Members</td>
<td>1'980'350</td>
<td>1'977'850</td>
</tr>
<tr>
<td>Income from Corporate Sponsor</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fundraising</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Congresses</td>
<td>1'400'000</td>
<td>1'600'000</td>
</tr>
<tr>
<td>Focused Meetings</td>
<td>187'788</td>
<td>65'000</td>
</tr>
<tr>
<td>Education group</td>
<td>29'275</td>
<td>20'000</td>
</tr>
<tr>
<td>Communication group</td>
<td>340'618</td>
<td>200'000</td>
</tr>
<tr>
<td>Other Income</td>
<td>103'500</td>
<td>163'500</td>
</tr>
<tr>
<td>Interest / Currency</td>
<td>91'193</td>
<td>60'170</td>
</tr>
<tr>
<td>Extraordinary Income</td>
<td>300'000</td>
<td>300'000</td>
</tr>
</tbody>
</table>
## Statement 2018 - Expenses as of December 31st

<table>
<thead>
<tr>
<th>Category</th>
<th>Statement December 31st 2018</th>
<th>Budget 2018 ExCom 02.02.2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Expenses</strong></td>
<td>4'280'241</td>
<td>5'658'640</td>
</tr>
<tr>
<td>A) Congress &amp; Events</td>
<td>45'393</td>
<td>50'000</td>
</tr>
<tr>
<td>B) Education</td>
<td>403'869</td>
<td>613'100</td>
</tr>
<tr>
<td>C) Communication &amp; Membership</td>
<td>365'396</td>
<td>558'500</td>
</tr>
<tr>
<td>D) Scientific Activities</td>
<td>714'818</td>
<td>1'370'850</td>
</tr>
<tr>
<td>E) External Strategic activities (outreach)</td>
<td>10'293</td>
<td>30'000</td>
</tr>
<tr>
<td>F) Internal activities (general admin &amp; HQ)</td>
<td>2'395'164</td>
<td>2'986'190</td>
</tr>
<tr>
<td>G) Extraordinary expenses (roll over income congress)</td>
<td>300'000</td>
<td>0</td>
</tr>
<tr>
<td>H) Contingency</td>
<td>45'308</td>
<td>50'000</td>
</tr>
</tbody>
</table>
### Statement 2018 - Summary

<table>
<thead>
<tr>
<th></th>
<th>2018 (YTD) in EURO</th>
<th>Statement December 31st 2018</th>
<th>Budget 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Income</strong></td>
<td>4'756'024</td>
<td>4'686'520</td>
<td></td>
</tr>
<tr>
<td><strong>Total Expenditures</strong></td>
<td>4'280'241</td>
<td>5'658'640</td>
<td></td>
</tr>
<tr>
<td><strong>within budget/-overspent</strong></td>
<td>475'782</td>
<td>-972'120</td>
<td></td>
</tr>
<tr>
<td><strong>projects on hold</strong></td>
<td></td>
<td></td>
<td>165'000</td>
</tr>
<tr>
<td>Adjustment ZKB investment to market value</td>
<td></td>
<td>-75'435</td>
<td></td>
</tr>
<tr>
<td><strong>+Surplus/-Deficit</strong></td>
<td>400'347</td>
<td>-1'137'120</td>
<td></td>
</tr>
</tbody>
</table>
Report of the mandatory auditors

to the management of

European Academy of Allergy and Clinical Immunology, Zürich

As mandatory auditors, we have audited the financial statements (balance sheet and income statement) of European Academy of Allergy and Clinical Immunology for the year ended 31 December 2018.

These financial statements (balance sheet and income statement) are the responsibility of the board of directors.

Our responsibility is to express an opinion on these financial statements based on our audit. Our audit was conducted in accordance with auditing standards promulgated by the Swiss professional, which require that an audit be planned and performed to obtain reasonable assurance about whether the financial statements are free from material misstatement. We have examined on a test basis evidence supporting the amounts and disclosures in the financial statements. We have also assessed the accounting principles used, significant estimates made and the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the accounting records and financial statements (balance sheet and income statement) comply with Swiss law.

5405 Baden, May 15th, 2019

MEIER & PARTNER AG

Christian Pfister
Licensed Audit Expert

www.meierpartnerag.ch • 5405 Baden • Tel. 0041 79 33 14 614 • info@meierpartnerag.ch
Approval of the Treasurer’s Report
Election of the Executive Committee 2019-2021
<table>
<thead>
<tr>
<th>EAACI Role</th>
<th>Name</th>
<th>Family Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Marek</td>
<td>Jutel</td>
<td>Poland</td>
</tr>
<tr>
<td>Secretary General</td>
<td>Jürgen</td>
<td>Schwarze</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Liam</td>
<td>O’Mahony</td>
<td>Ireland</td>
</tr>
<tr>
<td>Vice President Congresses</td>
<td>Edward</td>
<td>Knol</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Vice President Science</td>
<td>Tomás</td>
<td>Chivato</td>
<td>Spain</td>
</tr>
<tr>
<td>Vice President Communication &amp; Membership</td>
<td>Karin</td>
<td>Hoffmann-Sommergruber</td>
<td>Austria</td>
</tr>
<tr>
<td>Vice-President Education &amp; Specialty</td>
<td>Stefano</td>
<td>Del Giacco</td>
<td>Italy</td>
</tr>
<tr>
<td>Past President</td>
<td>Ioana</td>
<td>Agache</td>
<td>Romania</td>
</tr>
<tr>
<td>Chair, Asthma Section</td>
<td>Matteo</td>
<td>Bonini</td>
<td>Italy</td>
</tr>
<tr>
<td>Chair, Dermatology Section</td>
<td>Charlotte</td>
<td>Mortz</td>
<td>Denmark</td>
</tr>
<tr>
<td>Chair, ENT Section</td>
<td>Ludger</td>
<td>Klimek</td>
<td>Germany</td>
</tr>
<tr>
<td>Chair, Basic &amp; Clinical Immunology Section</td>
<td>Eva</td>
<td>Untersmayr-Elsenhuber</td>
<td>Austria</td>
</tr>
<tr>
<td>Chair, Pediatrics Section</td>
<td>Helen</td>
<td>Brough</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Chair, JM Assembly</td>
<td>Carmen</td>
<td>Riggioni</td>
<td>Spain</td>
</tr>
<tr>
<td>Interest Group Representative</td>
<td>Jolanta</td>
<td>Walusiak-Skorupa</td>
<td>Poland</td>
</tr>
<tr>
<td>Interest Group Representative</td>
<td>Oscar</td>
<td>Palomares</td>
<td>Spain</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Antti</td>
<td>Lauerma</td>
<td>Finland</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Oliver</td>
<td>Pfaar</td>
<td>Germany</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Maria</td>
<td>Torres</td>
<td>Spain</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Isabel</td>
<td>Skypala</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Markus</td>
<td>Ollert</td>
<td>Luxembourg</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Asli</td>
<td>Gelincik</td>
<td>Turkey</td>
</tr>
</tbody>
</table>
Presidential Programme
2019-2021
My vision for EAACI
The fundamentals for EAACI growth, stability and credibility

**Sustainable and healthy development**
- proper governance
- communication between ExCom, EAACI Family, Membership, HQ and key stakeholders
- organisational effectiveness
- sufficient resources

**EAACI as a member-driven organisation**
- strong values and ethics
- membership career development support and networking

**World’s Leader in Science and Education**
- research, training and innovation
- purposeful education: up-to-date and matching the needs of EAACI members, and other stakeholders

**Strong specialty**
- recognition of allergy and asthma as major social problems
- advocacy and networking
- translational and implementation science
Current status

EAACI has worked-up its place as:

• World’s largest and most influential allergy, asthma and clinical immunology organisation at the forefront of basic, translational and implementation science, education and health advocacy

• Coherent networking platform serving the variety of its stakeholders including HCPs, patients, HC policymakers and industry
Challenges

With > 11 000 members, 6 Sections, 6 IGs, 12 WGs, > 30 TF, large HQ, EAACI has become a much more complex organisation facing great challenges due to:

• constantly changing environment
• need for consolidation as the result of its very rapid growth
• However new opportunities for EAACI and its members
Challenges

"Internet, smartphones and big data are making possible the third Industrial Revolution."

Jeremy Rifkin
EAACI will use its unique position to ensure

- close collaboration of all relevant stakeholders
- best possible global access to innovative and affordable diagnostics and therapeutics in the allergy and clinical immunology
- for the benefit of the healthcare
The major focus during the term 2019-2021

Maintaining the organizational health:
- Proper Governance
- Strong finances
- Strong Ethics
- Organisational culture
- EAACI values

Front science:
- Congress focused meetings, master classes and allergy schools
- Journals
- Promoting research priorities in allergy, asthma and clinical immunology

Delivering of up-to-date purposeful education:
- E-Education
- Encouraging the talent development
- Leading Projects especially EAACI guidelines and PP

Support of membership:
- Networking
- Career development offer to the membership

Good communication between:
- ExCom
- Broad EAACI Family
- Membership
- Key stakeholders

Stimulating community:
- Outreach and branding – NAS, partnerships, PO, EU lobbying
- Mobile Health developments and novel digital tools
Support EAACI Family and the members

EAACI as the member-oriented Society
Membership - Attract and be Attractive!

Attract more new members

Make ourselves more attractive for the current members
Support EAACI Family

Forming strategic alliances

- European Strategic Forum on Allergic Diseases 2018”
Think long term!

Change is not so much about embracing a new idea, but being the first to forget an old one.
Why should we commit to EAACI?

We adhere to moral and ethical principles and work honestly and fairly with our patients and with each other.
Any other business